Markers of left ventricular decompensation in aortic stenosis
Calvin W L Chin1, Vassilis Vassiliou, William S A Jenkins
1BHF/Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
Insights
Calcified aortic stenosis leads to left ventricular hypertrophy and heart failure. Novel biomarkers may improve timing for aortic valve replacement, optimizing patient outcomes.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure
Background:
- Calcified aortic stenosis (CAS) causes left ventricular hypertrophy (LVH) as an adaptive response.
- LVH can progress to ventricular decompensation and heart failure.
- Current guidelines for aortic valve replacement (AVR) rely on symptoms or reduced ejection fraction (EF <50%).
Purpose of the Study:
- To review the pathophysiology of LVH in CAS and its transition to heart failure.
- To explore novel biomarkers for identifying this transition.
- To guide optimal timing for AVR.
Main Methods:
- Literature review of pathophysiology.
- Analysis of current guidelines for AVR.
- Exploration of emerging biomarkers.
Main Results:
- Symptoms and reduced ejection fraction are imperfect indicators for AVR timing.
- LVH progression to heart failure is a critical determinant for intervention.
- Novel biomarkers show potential for earlier and more accurate detection of decompensation.
Conclusions:
- Early identification of decompensation is crucial for timely AVR.
- Novel biomarkers may offer improved prognostic value over current methods.
- Optimizing AVR timing can improve outcomes in patients with severe aortic stenosis.
Abstract:
Calcified aortic stenosis is a condition that affects the valve and the myocardium. As the valve narrows, left ventricular hypertrophy occurs initially as an adaptive mechanism to maintain cardiac output. Ultimately, the ventricle decompensates and patients transition towards heart failure and adverse events. Current guidelines recommend aortic valve replacement in patients with severe aortic stenosis and evidence of decompensation based on either symptoms or an impaired ejection fraction <50%. However, symptoms can be subjective and correlate only modestly with the severity of aortic stenosis whilst impaired ejection fraction is an advanced manifestation and often irreversible. In this review, the authors will discuss the pathophysiology of left ventricular hypertrophy and the transition to heart failure. Subsequently, the authors will examine novel biomarkers that may better identify the transition from hypertrophy to heart failure and therefore guide the optimal timing for aortic valve replacement.
More Related Videos
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Stenosis I: Introduction
Aortic Regurgitation III: Medical Management
Mitral Regurgitation I: Introduction


